Beta thalassemia - a review

Jha, Rohan; Jha, Sanjay Kumar

doi:10.3126/jpn.v4i8.11609

Cited by 17 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The age average of the children in the MBT group was 10 years 3 months. MBT is usually diagnosed when the children are under 2 years old [9]. In this re- search, respondents in the MBT group had got regular PRC transfusion every 1-2 months for many years.…”

Section: Statistical Analysesmentioning

confidence: 99%

Correlation between Serum Ferritin and Cardiac Troponin I in Major Beta Thalassemia Children

Shodikin

Suwarniaty

Nugroho

2016

JTLS

View full text Add to dashboard Cite

Major beta thalassemia (MBT) is a hereditary disease which synthesies defects in beta chains of haemoglobin, it is causes red blood cell destruction and the symptoms of anemia. Red blood cell destruction, frequent blood transfusion and low adherence to routine use of iron chelator lead to iron accumulation in the heart, liver and endocrine organs. Accumulation of iron in the myocard can lead acute myocardial infarction. One of cardiac markers that had been used for the diagnosis of myocardial infarction was cardiac troponin I (cTnI). The aim of this research is find the correlation between serum ferritin levels and cTnI in MBT children. A descriptive analytic research was conducted using a cross sectional design. The subjects were divided into 2 groups, the MBT group and the control group. In both groups, the serum ferritin and cTnI levels ere evaluated. Data were analyzed using t-test and Pearson correlation test. Eleven children in the MBT group and 11 children in the control group were involved in this study. In the MBT group, the mean of serum ferritin and cTnI levels were 4292.5 µg/L and 0.20 ng/mL respectively. The mean of serum ferritin levels in the MBT group were higher than in the control and statistically significant (p= 0.0004). The mean of serum ferritin levels in the MBT group were higher than in the control and statistically significant (p= 0.0004). The mean of serum cTnI in the MBT group were higher than in the control, but statistically not significant (p= 0.82). In the MBT group, there was a weak corellation between serum ferritin and cTnI levels (r= 0.34).

show abstract

Section: Statistical Analysesmentioning

confidence: 99%

Correlation between Serum Ferritin and Cardiac Troponin I in Major Beta Thalassemia Children

Shodikin

Suwarniaty

Nugroho

2016

JTLS

View full text Add to dashboard Cite

show abstract

“…Side effects were reported according to BNF 74, and drugs monograms (Novartis), side effects associated with impaired QoL in thalassemia patients. Fatigue was significantly higher in pediatrics (P˂0.05); urinary discoloration and permanent skin reaction were significantly higher in adults (P˂0.05), as illustrated in table (3).…”

Section: Reported Side Effects With Icts Usagementioning

confidence: 96%

“…Beta thalassemia syndrome is a group of hereditary blood disorders that are mainly characterized by reduction or absence of β-globin chain synthesis, resulting in a reduction of hemoglobin in red blood cells (RBCs), decreased production of RBCs and consequently anemia (1,2) . Thalassemia disease was first described by Thomas B. Cooley and pearl Lee in 1925 (2,3) . In Iraq, there is a high prevalence of β-TM.…”

Section: Introductionmentioning

confidence: 99%

Evaluating Health-Related Quality of Life (HRQoL) in Iraqi Adult and Pediatric Patients with Beta-Thalassemia Major Using Two Different Iron Chelation Therapies

Shawkat¹,

Jwaid²,

Awad³

2019

IJPS

View full text Add to dashboard Cite

show abstract

“…In Iraq, there is a high prevalence of β-thalassemia major (β-TM) (the prevalence rate in 2015 was 27.4/100,000 populations) [4]. β-TM refers to a severe phenotype which occurs when patients are homozygous or compounds heterozygous for β chain mutation (β+/β0, β0/β0), patients commonly present with symptoms within the first 2 years of life [5,6]. The cornerstone management for patients with β-TM is based on lifelong transfusion and iron chelation [7].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Osteopathy in Patients With Beta-Thalassemia Major Using Different Iron Chelation Therapies

Shawkat

Jwaid

Awad

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: We aim to assess the bone mineral density (BMD) and bone biochemical parameters in Iraqi patients with β-thalassemia major (β-TM).Methods: Dual-energy X-ray absorptiometry scan was used to evaluate bone density and interpreted about Z-score which compares to the BMD of age-, sex-, and ethnicity-matched reference population. Biochemical parameters such as calcium, 25-OH Vitamin D, parathyroid hormone, and serum ferritin (SF) evaluated.Results: No statistical difference in SF between pediatrics and adults was determined; however, 66 patients were having their SF between 1000 and 2500 ng/ml and 122 patients with SF ˃2500 ng/ml. Calcium and Vitamin D levels are low in both adults and pediatrics. The bone status shows high percentages of osteoporosis 62% and 54.5% for pediatrics and adults, respectively, as well as osteopenia 27% and 34.3% for both pediatric and adults and to a lesser extent normal bone status 11% for each. Conclusion: Osteopathy has a high prevalence in Iraqi patients with β-TM and should receive an optimal transfusion and chelation therapy to prevent bone expansion. Calcium and Vitamin D should be routinely determined to prevent deficiency.

show abstract

Beta thalassemia - a review

Cited by 17 publications

References 18 publications

Correlation between Serum Ferritin and Cardiac Troponin I in Major Beta Thalassemia Children

Correlation between Serum Ferritin and Cardiac Troponin I in Major Beta Thalassemia Children

Evaluating Health-Related Quality of Life (HRQoL) in Iraqi Adult and Pediatric Patients with Beta-Thalassemia Major Using Two Different Iron Chelation Therapies

Evaluation of Osteopathy in Patients With Beta-Thalassemia Major Using Different Iron Chelation Therapies

Contact Info

Product

Resources

About